UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C.  20549 

SCHEDULE 13G
(Rule 13d-102)

Information Statement Pursuant to Rules 13d-1 and 13d-2 
Under the Securities Exchange Act of 1934 
(Amendment No. )* 

Concert Pharmaceuticals, Inc.
 (Name of Issuer)

Common Stock
(Title of Class of Securities)

206022105 
(CUSIP Number) 
 

February 19, 2014 

(Date of Event Which Requires Filing of this Statement) 
 

Check the appropriate box to designate the rule pursuant to which this 
schedule is filed: 
 
[  ] Rule 13d-1(b) 
 
[ X ] Rule 13d-1(c) 
 
[  ] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting 
person's initial filing on this form with respect to the subject class 
of securities, and for any subsequent amendment containing information 
which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be 
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange 
Act of 1934 ("Act") or otherwise subject to the liabilities of that section 
of the Act but shall be subject to all other provisions of the Act (however, 
see the Notes).

CUSIP No.  206022105
13G
Page 2 of 7 Pages 


1.

NAME OF REPORTING PERSON

Brookside Capital Partners Fund, L.P.
       


2.
                                                                 (a)		0
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
                                                                 (b) 		0

3.

SEC USE ONLY


4.

CITIZENSHIP OR PLACE OF ORGANIZATION
       Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5.

SOLE VOTING POWER

	1,147,833 Shares


6.

SHARED VOTING POWER
	0


7.

SOLE DISPOSITIVE POWER  

	1,147,833 Shares


8.

SHARED DISPOSITIVE POWER
	0

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

	1,147,833 Shares

10.
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES 
CERTAIN SHARES

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	

6.67%

12. 

TYPE OF REPORTING PERSON
              PN



      
      
CUSIP No.  206022105
13G
Page 3 of 7 Pages 
      

13.

NAME OF REPORTING PERSON

Brookside Capital Trading Fund, L.P.
       


14.
                                                                 (a)		0
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
                                                                 (b) 		0

15.

SEC USE ONLY


16.

CITIZENSHIP OR PLACE OF ORGANIZATION
       Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

17.

SOLE VOTING POWER

	350,000 Shares


18.

SHARED VOTING POWER
	0


19.

SOLE DISPOSITIVE POWER  

	350,000 Shares


20.

SHARED DISPOSITIVE POWER
	0

21.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

	350,000 Shares

22.
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES 
CERTAIN SHARES

23.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	

2.03%

24. 

TYPE OF REPORTING PERSON
              PN
      





Item 1(a).	Name of Issuer
       The name of the issuer to which this filing on Schedule 13G 
relates is Concert Pharmaceuticals, Inc. (the "Company").

Item 1(b).	Address of Issuer's Principal Executive Offices
       The principal executive offices of the Company are located at 99 
Hayden Avenue, Suite 500, Lexington, Massachusetts 02421.

Item 2(a).	Name of Person Filing
	This Statement is being filed on behalf of the following 
(collectively, the "Reporting Persons"): (1) Brookside Capital Partners 
Fund, L.P., a Delaware limited partnership ("Partners Fund"), whose sole 
general partner is Brookside Capital Investors, L.P., a Delaware limited 
partnership ("Brookside Investors"), whose sole general partner is Brookside 
Capital Management, LLC, a Delaware limited liability company ("Brookside 
Management"); and (2) Brookside Capital Trading Fund, L.P., a Delaware 
limited partnership ("Trading Fund"), whose sole general partner is 
Brookside Capital Investors II, L.P., a Delaware limited partnership 
("Brookside Investors II"), whose sole general partner is Brookside Management.
    
	The Reporting Persons have entered into a Joint Filing Agreement, 
dated February 28, 2014, a copy of which is filed with this Schedule 13G 
as Exhibit A, pursuant to which the Reporting Persons have agreed to file 
this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) 
under the Securities Exchange Act of 1934.

Item 2(b).	Address of Principal Business Office or, if none, Residence
       The principal business address of each of the Partners Fund, the 
Trading Fund, Brookside Investors, Brookside Investors II, and Brookside 
Management is John Hancock Tower, 200 Clarendon Street, Boston, MA 02116.

Item 2(c).	Citizenship
       Each of the Partners Fund, Trading Fund, Brookside Investors, 
Brookside Investors II and Brookside Management is organized under the 
laws of the State of Delaware.  

Item 2(d).	Title of Class of Securities
       The class of equity securities of the Company to which this filing 
on Schedule 13G relates is Common Stock ("Common Stock").

Item 2(e).	CUSIP Number
       The CUSIP number of the Company's Common Stock is 206022105.

Item 3.	If this statement is filed pursuant to Sections 240.13d-1(b) or 
240.13d-2(b) or (c), check whether the person filing is a:   

(a)	[  ]  Broker or dealer registered under section 15 of the 
Act (15 U.S.C. 78o).

(b)	[  ]  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 73c). 

(c)	[  ]  Insurance company as defined in section 3(a)(19) of the Act 
(15 U.S.C. 78c).

(d)	[  ]  Investment company registered under section 8 of the Investment 
Company Act of 1940 (15 U.S.C. 80a-8). 

(e)	[  ]  An investment adviser in accordance with Section 13d-1(b)(1)(ii)(E).

(f)	[  ]  An employee benefit plan or endowment fund in accordance 
with Section 240.13d-1(b)(1)(ii)(F). 

(g)	[  ]  A parent holding company or control person in accordance 
with Section 240.13d-1(b)(1)(ii)(G).

(h)	[  ]  A savings association as defined in Section 3(b) of the 
Federal Deposit Insurance Act (12 U.S.C. 1813). 

(i)	[  ]  A church plan that is excluded from the definition of 
an investment company under section 3(c)(14) of the Investment Company 
Act of 1940 (15 U.S.C. 80a-3). 

(j)	[  ]  Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).

  	[x]  If this statement is filed pursuant to Section 240.13d-1(c), check 
	     this box. 

Item 4.	Ownership

Item 4(a).  Amount beneficially owned  
       As of the close of business on February 19, 2014, the Partners Fund 
held 1,147,833 Shares of Common Stock. As of the close of business on 
February 19, 2014, the Trading Fund held 350,000 Shares of Common Stock. 
As a result of the foregoing and the relationships described in Item 2(a), 
the Reporting Persons may be deemed to beneficially own 1,497,833 shares 
of the Common Stock of the Company as of February 19, 2014.

Item 4(b).  Percent of Class
      As of the close of business on February 19, 2014, the Partners 
Fund held 6.67% of the Common Stock of the Company. As of the close of 
business on February 19, 2014, the Trading Fund held 2.03% of the 
Common Stock of the Company. The aggregate percentage of Common 
Stock reported owned by the Reporting Persons is 8.70% of the Common 
Stock of the Company as of February 19, 2014 and is based upon 17,218,121 
shares of Common Stock outstanding, which is the total number of shares 
of Common Stock outstanding as of February 12, 2014, based on representations 
made in the Company's prospectus filed pursuant to Rule 424(b)(4) under the 
Securities Act of 1933 with the Securities and Exchange Commission on 
February 12, 2014.

Item 4(c).  Number of shares as to which such person has:

	(i)	sole power to vote or to direct the vote:	1,497,833 Shares	
 
       (ii)	shared power to vote or to direct the vote:	0
      
	(iii)	sole power to dispose or to direct the	disposition of:	1,497,833 Shares
       
       (iv)	shared power to dispose or to direct the disposition of: 0

Item 5.	Ownership of Five Percent or Less of a Class

       Not Applicable.

Item 6.	Ownership of More than Five Percent on Behalf of Another Person

       Not Applicable. 

Item 7.	Identification and Classification of the Subsidiary which Acquired 
the Security Being Reported on by the Parent Holding Company:

       Not Applicable. 

Item 8.	Identification and Classification of Members of the Group 

       Not Applicable.

Item 9.	Notice of Dissolution of Group 

       Not Applicable.






Item 10.	Certification
       By signing below, the undersigned certifies that, to the best of 
its knowledge and belief, the securities referred to above were not 
acquired and are not held for the purpose of or with the effect of 
changing or influencing the control of the issuer of the securities 
and were not acquired and are not held in connection with or as a 
participant in any transaction having that purpose or effect.

Dated:  February 28, 2014
       After reasonable inquiry and to the best of my knowledge and 
belief, I certify that the information set forth in this statement 
is true, complete, and correct.

                          BROOKSIDE CAPITAL PARTNERS FUND, L.P.
                                           	
                    By: Brookside Capital Investors, L.P.,
                    its general partner
                    By: Brookside Capital Management, LLC,
                    its general partner			


                               	By: /s/ William E. Pappendick IV
                              Name: William E. Pappendick IV
                              Title: Managing Director
                          
                          
                          BROOKSIDE CAPITAL TRADING FUND, L.P.
                                           	
                    By: Brookside Capital Investors II, L.P.,
                    its general partner
                    By: Brookside Capital Management, LLC,
                    its general partner			


                               	By: /s/ William E. Pappendick IV
                              Name: William E. Pappendick IV
                              Title: Managing Director


Exhibit A 

AGREEMENT REGARDING THE JOINT FILING OF
SCHEDULE 13G

  
The undersigned hereby agree as follows: 

(i) The Statement on Schedule 13G, and any amendments thereto, to 
which this Agreement is annexed as Exhibit A is and will be filed 
on behalf of each of them in accordance with the provisions of 
Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended; 
and 

(ii) Each of them is responsible for the timely filing of such Schedule 
13G and any amendments thereto, and for the completeness and accuracy 
of the information concerning such person contained therein; but 
none of them is responsible for the completeness or accuracy of the 
information concerning the other persons making the filing, unless such 
person knows or has reason to believe that such information is 
inaccurate. 

Dated:  February 28, 2014

     BROOKSIDE CAPITAL PARTNERS FUND, L.P.
                                           	
                    By: Brookside Capital Investors, L.P.,
                    its general partner
                    By: Brookside Capital Management, LLC,
                    its general partner			


                               	By: /s/ William E. Pappendick IV
                              Name: William E. Pappendick IV
                              Title: Managing Director
                          
                          
                          BROOKSIDE CAPITAL TRADING FUND, L.P.
                                           	
                    By: Brookside Capital Investors II, L.P.,
                    its general partner
                    By: Brookside Capital Management, LLC,
                    its general partner			


                               	By: /s/ William E. Pappendick IV
                              Name: William E. Pappendick IV
                              Title: Managing Director